Stifel has initiated coverage of Cytokinetics (CYTK) with a buy rating, citing its drug aficamten, valuation and upcoming ...

Edgewise Therapeutics (EWTX) stock traded flat as Stifel launched its coverage with a Hold recommendation, indicating a ...

Stifel Nicolaus analyst Brad Reback maintained a Buy rating on Workiva (WK – Research Report) today and set a price target of $130.00. The ...

Stifel raised the firm’s price target on Werner (WERN) to $35 from $30 and keeps a Hold rating on the shares. 2024 largely proved to be “the ...

Thursday, January 23, 2025, marks the release of a new report by Stifel analysts on the US transport sector. The report outlines a cautious perspective on the industry's future, noting that while 2024 ...

CEO Ron Kruszewski and Yahoo Finance Executive Editor Brian Sozzi at the 2025 World Economic Forum in Davos, Switzerland, to talk about the macro issues impacting the investment banking firm, ...

Stifel analyst Brian Brophy raised the firm’s price target on Quanta Services (PWR) to $388 from $374 and keeps a Buy rating ...

Stifel CEO Ron Kruszewski discusses banks' M&A space and market valuation ahead of the new US administration's policy. Kruszewski speaks to Bloomberg's Lisa Abramowicz on the sidelines of the 2025 ...

Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, ...

On Wednesday, Vince Holding Corp (VNCE) stock saw a decline, ending the day at $2.35 which represents a decrease of $-0.60 or -20.34% from the prior close of $2.95. The stock opened at $2.95 and ...

Canadian investment dealer Eight Capital Corp. is winding down and many of its top staff are headed to Stifel Financial Corp.

Equities researchers at Stifel Canada lifted their FY2024 earnings per share (EPS) estimates for shares of Kits Eyecare in a research note issued on Monday, January 20th. Stifel Canada analyst M.